 SAN DIEGO, Dec. 08, 2022 GLOBE NEWSWIRE Prometheus Biosciences, Inc. Nasdaq: RXDX, a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced the pricing of an underwritten offering of 4,545,455 shares of its common stock ... The post Prometheus Biosciences, Inc. Announces Pricing of Public Upsized ... 